The impact of genetic markers on the diagnosis of lung cancer: A current perspective

Journal of Thoracic Oncology

Volumn 2, Issue 11, 2007, Pages 1044-1051

  Chorostowska Wynimko, Joanna ^a   Szpechcinski, Adam ^a  

^a NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

Author keywords

Biomarkers; Bronchoalveolar lavage; Exhaled breath condensate; Lung cancer; Plasma DNA; Sputum

Indexed keywords

BIOLOGICAL MARKER; DEATH ASSOCIATED PROTEIN KINASE; FRAGILE HISTIDINE TRIAD PROTEIN; K RAS PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P16; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; RIBONUCLEOPROTEIN; TELOMERASE REVERSE TRANSCRIPTASE;

CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; DIAGNOSTIC VALUE; EARLY CANCER; EARLY DIAGNOSIS; EXHALATION; GENETIC MARKER; HUMAN; LUNG CANCER; LUNG LAVAGE; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; TREATMENT OUTCOME;

EID: 35848969074     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318158eed4     Document Type: Review

References (58)

1. Stewart BW, Kleihues P, eds. World Cancer Report. Lyon, IARC, 2003.
2. Gregor A, Thompson CS, Brewster DH, et al. Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study. Thorax 2001;56:212-217.
3. Sonobe M, Tanaka F, Wada H. Lung cancer-related genes in the blood. Ann Thorac Cardiovasc Surg 2004;10:213-217.
4. Brambilla C, Fievet F, Jeanmart M, et al. Early detection of lung cancer: role of biomarkers. Eur Respir J Suppl 2003;39:36-44.
5. Kennedy TC, Hirsch R. Using molecular markers in sputum for the early detection of lung cancer: a review. Lung Cancer 2004;45(Suppl):21-27.
6. Palcic B, Garner DM, Beveridge J, et al. Increase of sensitivity of sputum cytology using high-resolution image cytometry: field study results. Cytometry 2002;50:168-176.
7. Johnson FL, Turic B, Kemp R, et al. Improved diagnostic sensitivity for lung cancer using an automated quantitative cytology system and uridine 5′-triphosphate-induced sputum specimens. Chest 2004;125:157S-158S.
8. McWilliams A, Mayo J, MacDonald S, et al. Lung cancer screening: a different paradigm. Am J Respir Crit Care Med 2003;168:1167-1173.
9. Tockman MS, Mulshine JL, Piantadosi S, et al. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res 1997;3:2237-2246.
10. Sueoka E, Sueoka N, Goto Y, et al. Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia. Cancer Res 2001;61:1896-1902.
11. Sokolova IA, Bubendorf L, O'Hare A, et al. A fluorescence in situ hybridization-based assay for improved detection of lung cancer cells in bronchial washing specimens. Cancer 2002;96:306-315.
12. Varella-Garcia M, Kittelson J, Schulte AP, et al. Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer. Cancer Detect Prev 2004;28:244-251.
13. Kettunen E, Salmenkivi K, Vuopala K, et al. Copy number gains on 5p15, 6p11-q11, 7p12, and 8q24 are rare in sputum cells of individuals at high risk of lung cancer. Lung Cancer 2006;54:169-176.
14. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891-11896.
15. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-5958.
16. Belinsky SA, Klinge DM, Dekker JD, et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 2005;11:6505-6511.
17. Cirincione R, Lintas C, Conte D, et al. Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study. Int J Cancer 2006;118:1248-1253.
18. Olaussen KA, Soria JC, Park YW, et al. Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC. Eur J Cancer 2005;41:2112-2119.
19. Ahrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999;91:332-339.
20. Ferretti G, Curigliano G, Pastorino U, et al. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. Clin Cancer Res 2000;6:2393-2400.
21. Topaloglu O, Hoque MO, Tokumaru Y, et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 2004;10:2284-2288.
22. Fielding P, Turnbull L, Prime W, et al. Heterogeneous nuclear ribonucleoprotein A2/B1 up-regulation in bronchial lavage specimens: a clinical marker of early lung cancer detection. Clin Cancer Res 1999;5:4048-4052.
23. Chan EC, Lam SY, Tsang KW, et al. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage. Clin Cancer Res 2002;8:3741-3746.
24. Carstensen T, Schmidt B, Engel E, et al. Detection of cell-free DNA in bronchial lavage fluid supernatants of patients with lung cancer. Ann N Y Acad Sci 2004;1022:202-210.
25. Schmidt B, Engel E, Carstensen T, et al. Quantification of free RNA in serum and bronchial lavage: a new diagnostic tool in lung cancer detection? Lung Cancer 2005;48:145-147.
26. Corradi M, Mutti A. Exhaled breath analysis: from occupational to respiratory medicine. Acta Biomed Ateneo Parmense 2005;76(Suppl):20-29.
27. Gessner C, Kuhn H, Toepfer K, et al. Detection of p53 gene mutations in exhaled breath condensate of non-small cell lung cancer patients. Lung Cancer 2004;43:215-222.
28. Carpagnano GE, Foschino-Barbaro MP, Mule G, et al. 3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. Am J Respir Crit Care Med 2005;172:738-744.
29. Wistuba Gazdar II, AF Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001;28:3-13.
30. Raptis L, Menard HA. Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus. J Clin Invest 1980;66:1391-1399.
31. Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow up of lung cancer patients. Cancer Res 2001;61:4675-4678.
32. Sozzi G, Conte D, Leon M, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003;21:3902-3908.
33. Herrera LJ, Raja S, Gooding WE, et al. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem 2005;51:113-118.
34. Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic acid as a prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004;22:4157-4164.
35. Chang HW, Lee SM, Goodman SN, et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as a diagnostic test for cancer. J Natl Cancer Inst 2002;94:1697-1703.
36. Chen XQ, Stroun M, Magnenat JL, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996;2:1033-1035.
37. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
38. Ramirez JL, Sarries C, de Castro PL, et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett 2003;193:207-216.
39. Fujiwara K, Fujimoto N, Tabata M, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005;11:1219-1225.
40. Bearzatto A, Conte D, Frattini M, et al. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res 2002;8:3782-3787.
41. An Q, Liu Y, Gao Y, et al. Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients. Cancer Lett 2002;188:109-114.
42. Zhou XM, Shao SJ, Xu GD, et al. Highly sensitive determination of the methylated p16 gene in cancer patients by microchip electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 2005;816:145-151.
43. Gonzalez R, Silva JM, Sanchez A, et al. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Ann Oncol 2000;11:1097-1104.
44. Beau-Faller M, Gaub MP, Schneider A, et al. Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer 2003;105:361-370.
45. Sanchez-Cespedes M, Monzo M, Rosell R, et al. Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann Oncol 1998;9:113-116.
46. Andriani F, Conte D, Mastrangelo T, et al. Detecting lung cancer in plasma with the use of multiple genetic markers. Int J Cancer 2004;108:91-96.
47. Trombino S, Neri M, Puntoni R, et al. Mutations in K-ras codon 12 detected in plasma DNA are not an indicator of disease in patients with non-small cell lung cancer. Clin Chem 2005;51:1313-1314.
48. Kopreski MS, Benko FA, Gocke CD. Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Ann N Y Acad Sci 2001;945:172-178.
49. Fleischhacker M, Beinert T, Ermitsch M, et al. Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann N Y Acad Sci 2001;945:179-188.
50. Sueoka E, Sueoka N, Iwanaga K, et al. Detection of plasma hnRNP B1 mRNA, a new cancer biomarker, in lung cancer patients by quantitative real-time polymerase chain reaction. Lung Cancer 2005;48:77-83.
51. Pelosi G, Schianchi E, Dell'orto P, et al. Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients. Virchows Arch 2006;448:7-15.
52. Fournie GJ, Courtin JP, Laval F, et al. P Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 1995;91:221-227.
53. Liu Y, An Q, Li L, et al. Hypermethylation of p16INK4α in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis 2003;24:1897-1901.
54. Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002;62:371-375.
55. Sozzi G, Musso K, Ratcliffe C, et al. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res 1999;5:2689-2692.
56. Khan S, Coulson JM, Woll PJ. Genetic abnormalities in plasma DNA of patients with lung cancer and other respiratory diseases. Int J Cancer 2004;110:891-895.
57. Bruhn N, Beinert T, Oehm C, et al. Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer. Ann N Y Acad Sci 2000;906:72-82.
58. Cuda G, Gallelli A, Nistico A, et al. Detection of microsatellite instability and loss of heterozygosity in serum DNA of small and non-small cell lung cancer patients: a tool for early diagnosis? Lung Cancer 2000;30:211-214.